Posted on April 29th, 2019
Once the diagnosis of malignant mesothelioma is made by your doctor, further tests such as imaging and biopsy will be performed to check the extent to which cancer has spread in your body. This process helps doctors start an appropriate treatment plan and improve your prognosis and can also help with your claim.
Mesothelioma staging is an essential part of the diagnostic procedure and a vital element in creating an individualized treatment plan. It also plays a major role in deciding the patient's eligibility for undergoing tumor removal surgery.
Mesothelioma has four stages: stage 1 mesothelioma is localized, the malignancy has not spread beyond the point of origin, whereas stages 2 through 4 are considered to be advanced stages.
When mesothelioma is diagnosed at a less advanced stage, people tend to have a better chance of getting successful treatment. But, as mesothelioma has a latency period of almost 2-3 decades and symptoms similar to that of other common diseases, many patients remain undiagnosed until they reach the advanced stage 3 or 4. At these stages, patients may have a worse prognosis due to the lack of curative treatment options.
The staging systems were developed specifically to stage malignant pleural mesothelioma. Researchers are working on adapting the TNM system for peritoneal mesothelioma. Because pericardial mesothelioma or testicular mesothelioma are rarer cancers, no formal systems have been created to stage them. The Tumor, Nodes, and Metastasis (TNM) Staging System was first developed in the 1940s by a French physician, Pierre Denoix. In the early 1980s A.P. Chahinian developed the first TNM staging system specific to mesothelioma.
The TNM staging system describes the important aspects of cancer in detail. The letter T stands for the tumor and explains the size and extent of the primary tumor, the letter N describes if the lymph nodes are affected, and the letter M refers to the metastasis or the spread of the tumor from the point of development to other parts of the body.
The tools used in clinical staging and prognostication include:
Currently, the TNM staging system is approved by the American Joint Committee on Cancer (AJCC) and is the most commonly used and often updated by new mesothelioma research. It is also referred to as the International Mesothelioma Interest Group (IMIG) staging system. In this system, the factors such as the size of the tumor, its extent, lymph node involvement, and metastasis are taken into account to classify the pleural mesothelioma stage.